- Home
- AMPY vs GLSI Comparison
AMPY vs GLSI Comparison
Compare AMPY & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPY
- GLSI
- Stock Information
- Founded
- AMPY 2011
- GLSI 2006
- Country
- AMPY United States
- GLSI United States
- Employees
- AMPY N/A
- GLSI N/A
- Industry
- AMPY Oil & Gas Production
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- AMPY Energy
- GLSI Health Care
- Exchange
- AMPY Nasdaq
- GLSI Nasdaq
- Market Cap
- AMPY 160.2M
- GLSI 149.5M
- IPO Year
- AMPY 2011
- GLSI 2020
- Fundamental
- Price
- AMPY $4.49
- GLSI $11.54
- Analyst Decision
- AMPY Strong Buy
- GLSI Strong Buy
- Analyst Count
- AMPY 1
- GLSI 1
- Target Price
- AMPY $11.00
- GLSI $39.00
- AVG Volume (30 Days)
- AMPY 399.2K
- GLSI 63.0K
- Earning Date
- AMPY 11-05-2025
- GLSI 11-13-2025
- Dividend Yield
- AMPY N/A
- GLSI N/A
- EPS Growth
- AMPY N/A
- GLSI N/A
- EPS
- AMPY 0.38
- GLSI N/A
- Revenue
- AMPY $279,289,100.00
- GLSI N/A
- Revenue This Year
- AMPY $2.33
- GLSI N/A
- Revenue Next Year
- AMPY N/A
- GLSI N/A
- P/E Ratio
- AMPY $11.70
- GLSI N/A
- Revenue Growth
- AMPY N/A
- GLSI N/A
- 52 Week Low
- AMPY $2.27
- GLSI $8.06
- 52 Week High
- AMPY $7.35
- GLSI $15.50
- Technical
- Relative Strength Index (RSI)
- AMPY 67.30
- GLSI 51.72
- Support Level
- AMPY $3.91
- GLSI $11.03
- Resistance Level
- AMPY $4.09
- GLSI $11.90
- Average True Range (ATR)
- AMPY 0.20
- GLSI 0.69
- MACD
- AMPY 0.04
- GLSI -0.01
- Stochastic Oscillator
- AMPY 99.35
- GLSI 39.42
About AMPY Amplify Energy Corp.
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The company's oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.